To assess the effect of this combination, we generated DCs pulsed with sarcoma cells and describe T cell and DC functional changes after treatment with (1) sunitinib, (2) nivolumab and (3) sunitinib with nivolumab, including T-cell subpopulation composition, T-cell proliferation and IFN-γ production. The gene discussed is IFNG; the disease is sarcoma.